CN105168723A - External traditional Chinese medicine composition for treating cancer pain and preparation method thereof - Google Patents
External traditional Chinese medicine composition for treating cancer pain and preparation method thereof Download PDFInfo
- Publication number
- CN105168723A CN105168723A CN201510675585.1A CN201510675585A CN105168723A CN 105168723 A CN105168723 A CN 105168723A CN 201510675585 A CN201510675585 A CN 201510675585A CN 105168723 A CN105168723 A CN 105168723A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine composition
- pain
- weight
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an external traditional Chinese medicine composition for treating a cancer pain. A preparation method of the traditional Chinese medicine composition comprises the following steps: grinding 25 to 35 parts by weight of dragon's blood, 4 to 6 parts by weight of venenum bufonis, 60 to 90 parts by weight of crude arisaema consanguineum schott, 60 to 90 parts by weight of common monkshood mother root, 25 to 35 parts by weight of natural indigo, 25 to 35 parts by weight of borneol, 50 to 70 parts by weight of frankincense and 50 to 70 parts by weight of myrrh into powder; sieving the powder by a 200-mesh sieve; adding appropriate auxiliary materials to prepare an external ointment or patch. The external traditional Chinese medicine composition can be used for effectively alleviating or eliminating the cancer pain.
Description
Technical field
The present invention relates to a kind of external medicine composition being used for the treatment of cancer pain, and the preparation method of said composition, belong to tcm field.
Background technology
Chronic cancer pain is then the chronic pain caused due to malignant tumor, and in the subjective symptoms of cancer patient, pain incidence rate is the highest.Have the malignant tumor patient of 25% ~ 40% first visit, 30 ~ 50% cancer patient during active treatment, can there is this symptom in the cancer progression phase in the patient of 70% ~ 90%, many cancer patients have to suffer from the considerable distress of cancer pain within the final stage time of life.According to investigations, have the patient of 61.6% ~ 69% with cancer pain in China, the patient with pain in inpatient accounts for 69%, and wherein mild pain accounts for 21.5%, and moderate pain accounts for 19%, and severe pain accounts for 28.5%.
Drug therapy is the main method of Pain Treatment.Mainly apply at present " three steps analgesia medicines " Therapeutic Method that WHO recommends clinically, its Therapeutic Principle roughly can be summarized as 5 points, that is: oral, on time, by ladder, individuation, attention detail.Concerning the patient of one-level (slightly) pain, mainly select antipyretic-antalgic agent class medicine as aspirin; Weak opioid drug should be selected, as codeine for secondary (moderate) pain; First-selected strong opiates medicine is answered, as morphine sheet etc. for three grades of (severe) pain.Its treatment, for Most patients, can alleviate its cancerous pain.But this type of poisonous side effect of medicine of life-time service is large, modal have constipation, calmness, nausea and vomiting, respiration inhibition etc., and dependency, by force additive, usually has a strong impact on the quality of life of patient.Therefore, how to reduce again unnecessary side effect in abundant analgesic simultaneously, become in current clinical position and be particularly badly in need of.
Summary of the invention
The object of this invention is to provide a kind of new external medicine composition, can effective treatment of cancer pain.The preparation method of said composition is provided simultaneously.
The present invention seeks to be achieved through the following technical solutions.
Scheme 1: a kind of external medicine composition for cancer pain, the effective ingredient of said composition is made up of the crude drug of following weight ratio: Sanguis Draxonis 25-35 part, Venenum Bufonis 4-6 part, Rhizoma Arisaematis 60-90 part, Radix Aconiti 60-90 part, Indigo Naturalis 25-35 part, Borneolum Syntheticum 25-35 part, Olibanum 50-70 part, Myrrha 50-70 part.
Preferably, the consisting of of above-mentioned each crude drug: Sanguis Draxonis 30 parts, Venenum Bufonis 5 parts, Rhizoma Arisaematis 75 parts, Radix Aconiti 75 parts, Indigo Naturalis 30 parts, Borneolum Syntheticum 30 parts, Olibanum 60 parts, Myrrha 60 parts.
Scheme 2: on the crude drug basis of scheme 1, increases Flos Rhododendri Mollis 2.5-3.5 part, Caulis Erycibes 25-35 part, Ramulus Cinnamomi 40-60 part.Preferably, the consisting of of above-mentioned three taste crude drug: Flos Rhododendri Mollis 3 parts, Caulis Erycibes 30 parts, Ramulus Cinnamomi 50 parts.
In prescription of the present invention: monarch drug Sanguis Draxonis, sweet-salty, flat, slightly poisonous, promoting blood circulation to remove blood stasis for oral administration, analgesic therapy, external hemostasia and promoting granulation, sore; Ministerial drug Indigo Naturalis removing heat from blood, removing toxic substances, heat clearing away, have the inhibitory action of moderate strength to animal transplanting tumor; Cool, the micro-poison of Bufo siccus acrid in the mouth, gas, has removing toxic substances, pain relieving, opens effect of refreshment; Radix Aconiti acrid in the mouth is bitter, hot, very toxic, removing mass gathers, and has effect of wind-damp dispelling, antalgic; Rhizoma Arisaematis bitter in the mouth, pungent, warm, having drying dampness to eliminate phlegm, expelling wind to relieve convulsion, external mass dissipating and swelling eliminating, is ministerial drug altogether; Adjuvant drug Borneolum Syntheticum, acrid in the mouth is bitter, micro-cool, and have refreshment of having one's ideas straightened out, promoting blood circulation to restore menstrual flow, effect of reducing swelling and alleviating pain, topical application has analgesic effect, and its composition elemi Recording has the function promoting Drug Percutaneous Absorption; Olibanum, Myrrha mutual reinforcement between are use, and Olibanum bitter in the mouth is pungent, temperature, and nontoxic, analgesic therapy of invigorating blood circulation, stretches muscle; Myrrha bitter in the mouth is pungent, temperature, nontoxic.All medicines share, and play detoxicating and resolving stagnation of pathogens altogether, the merit of reducing swelling and alleviating pain, cure mainly the pain caused by various cancerous protuberance, and card belongs to qi depression to blood stasis, and sees migratory pain, pain and swollen, and during pain, time slack is anxious, companion's distension and fullness of the chest and abdomen, belch; Or with twinge, localized pain, the also pain of pressing, very, dim complexion, purplish tongue has petechia ecchymosis to hypnalgia, and pulse condition is not smooth.
During use, each crude drug should be ground to the powder, cross 200 mesh sieves, obtain fine powder.Before using, clean painful area, then by medicamental pulverata boiled water furnishing pasty state, divides in Gypsum Fibrosum cotton pad, thickness is about 0.3cm, and area diameter is about greater than painful area skin 2cm, order mulching one deck gauze on ointment, layer of plastic film, and close fixing with desensitization adhesive plaster.Every day 1 time, application time 8 ~ 12h.
Beneficial effect
For proving the effect of medicine of the present invention, inventors performed a series of clinical research experiment, is below the main contents of experiment:
1. clinical data
1.1 case sources
Year March in March, 2011 to 2012, Gate of Pervasive Peace hospital of Chinese Chinese medical science institute oncology inpatient met the patient of diagnostic criteria.
1.1.1 diagnostic criteria
(1) meet the diagnosing tumor standard of International Union Against Cancer (UICC), through pathology and/or cytodiagnosis, or iconography binding specificity tumor marker is diagnosed as the inpatient of malignant tumor.
(2) with the patient of pain, and the etiological classification that bone aching specifies because belonging to WHO: namely directly invaded the pain caused by tumor development.
(3) standard of taking stopgap measures is demonstrate,proved, according to its clinical manifestation differentiation of symptoms and signs for classification of syndrome with reference to the 7th edition " Diagnostics of Chinese Medicine " cancer pain differentiation of symptoms and signs for classification of syndrome.
1.1.2 inclusive criteria
(1) clear and definite cancer pain patient is diagnosed; (reference of Western medicine diagnose standard " oncology ", " newly organized common cancer diagnosis and treatment specification ", " new Chinese medicine guideline of clinical investigations);
(2) age >=18 ,≤70 years old;
(3) body weight >=45kg;
(4) Ka Shi KPS scale (KPS) > 60 points, estimates more than 3 months life cycle;
(5) accept voluntarily the treatment of this drug test and the person that signs Informed Consent Form;
(6) during being intended to clinical trial together except third order convergence treatment, the other treatment for cancer pain is not used;
(7) inpatient;
1.1.3 exclusion standard
(1) above-mentioned inclusion criteria person is not met;
(2) with respiration inhibition, respiratory tract obstruction, anoxia, high hot person;
(3) there are the obvious heart, brain, Liver and kidney function obstacle person, or have hemorrhage and obvious bleeding tendency person;
(4) to opioid drug, ntipyretic analgesic medicine, alcohol intolerance and allergic constitution person;
(5) anemia of pregnant woman, women breast-feeding their children, child, psychotic;
(6) late period patient's condition danger severe one or be less than 3 months persons life cycle;
(7) drug dependence history is had;
(8) with spirit, disturbance of consciousness, can not cooperation estimator;
(9) just person in chemicotherapy.
2. therapeutic scheme
2.1 research groupings
This research is random, double blinding, placebo parallel check experiment.Adopt 6ASE.12 software simulation to produce random digit clinical research table, carry out medicine and compile blind and point medicine, the blind end, leaves Gate of Pervasive Peace hospital scientific research place and institution of clinical trial independently two places in duplicate respectively in subsequently.According to research approach screening and the satisfactory volunteer of typing, adopt envelope randomized, be randomized into treatment group (external medicine composition of the present invention) and matched group (placebo group) according to the sequencing of screening.
2.2 placebo make
Choose Chinese medicine Folium Isatidis as primary raw material, and add corresponding flavoring agent/aromatic; Consider that local skin can produce refrigerant sense after external application containing Borneolum Syntheticum in trial drug, therefore add the Herba Menthae Haplocalycis volatile oil of Pain Treatment without impact is simulated.Finally prepare same medicine for treatment profile, color, placebo that taste is all identical.After the placebo drying be successfully prepared, pulverizing, cross 200 mesh sieves, be distributed into clinical practice 30g used and pack pouch, for subsequent use.
2.3 observe medicine
2.3.1 medicine makes: the medicine composition of the embodiment of the present invention 1, will grind to the powder, and cross 200 mesh sieves, be distributed into the packaging pouch of 30g, for subsequent use.
2.3.2 technical specification:
2.3.2.1 prepare: choose relatively-stationary, the single painful area of patient as agents area, clean affected part before using.
2.3.2.2 medication: by 30g medicamental pulverata boiled water furnishing pasty state, divide in Gypsum Fibrosum cotton pad, thickness is about 0.3cm, and area diameter is about greater than painful area skin 2cm.
2.3.2.3 fix: order mulching one deck gauze on ointment, layer of plastic film, and close fixing with desensitization adhesive plaster.
2.3.2.4 the time: once a day, application time 6 hours.
2.4 Therapeutic Method
2.4.1 Primary Care: adopt the third order convergence drug usage that WHO recommends.
2.4.1.1I level ladder (representing medicine): draw U.S. pungent controlled release tablet of making an uproar;
2.4.1.2II level ladder (representing medicine): tramadol sustained-release sheet;
2.4.1.3III level ladder (representing medicine): MST Continus.
2.4.2 treatment group: stick external side of the present invention, 1 times/day, the course for the treatment of is 14d.
2.4.3 matched group: give the placebo that profile, color, excipient are all identical, 1 times/day, the course for the treatment of is 14d.
3. result of the test
3.1 pain relief degree
Pain relief degree: 0 degree: without alleviating (pain does not alleviate); 1 degree: minor responses (alleviating about 1/4); 2 degree: moderate alleviates (alleviating more than 1/2); 3 degree: obviously alleviate (alleviating about more than 3/4); 4 degree: complete incidence graph (disappearance); (pain relief rate) effective percentage=obvious effective rate (partial rcsponse+complete incidence graph)+minor effect rate (minor responses).Through statistical analysis, after treatment terminates, two groups of patient pain's degree of alleviation compare and have compared significant difference ((P < 0.05), of the present invention group of (30 example) total pain relief rate: 86.7%; Placebo group (30 example) total pain relief rate: 66.7%, the former is obviously better than the latter, refers to table one:
Table one: after treatment terminates, two groups of patient pain's degree of alleviation compare
| Group | Number of cases | 0 degree | 1 degree | 2 degree | 3 degree | 4 degree | Pain relief rate |
| Of the present invention group | 30 | 4(13.3％) | 3(10.0％) | 9(30.0％) | 6(20.0％) | 8(26.7％) | 86.7％ |
| Placebo group | 30 | 10(33.3％) | 10(33.3％) | 4(13.3％) | 4(13.3％) | 2(6.7％) | 66.7％ |
Note: through X
2, inspection, result is as follows: X
2=12.264, P=0.015 < 0.05.
3.2 dose slips
Dose slip: (at the end of entering to organize predose-observation dosage)/enter to organize predose × 100%; Through statistical analysis, after treatment terminates, two groups of patient pain's degree of alleviation have compared significant difference (P < 0.05), of the present invention group of (30 example) dose slip: 8.93 ± 6.72 (%); Placebo group (30 example) dose slip :-13.5 ± 7.40 (%), the former is obviously better than the latter, refers to table two:
Table two: after treatment terminates, two groups of patient's dose slips compare (%)
| Group | Number of cases | Dose slip (%) | Z value | P value |
| Of the present invention group | 30 | 8.93±6.72 | ||
| Placebo group | 30 | -13.5±7.40 | -2.761 | 0.006 |
Note: through Wilcoxon rank test, result is as follows: Z=-2.761, P=0.006 < 0.05.
3.3 tcm symptom comparitive study
Tcm symptom curative effect determinate standard: effective: after treatment, symptom integral comparatively treats front minimizing >=70%; Effective: after treatment, symptom integral reduces 36-69.9% before comparatively treating; Invalid: after treatment, symptom integral reduces < 36% before comparatively treating; Through statistical analysis, after treatment terminates, two groups of patients, two groups of tcm symptoms improve and have compared remarkable significant difference (P < 0.01), and the segmentation mausoleum pain-stopping external use side group (30 example) that disappears improves total effective rate: 83.3%; Placebo group (30 example) improves total effective rate: 6.6%, and the former is obviously better than the latter, refers to table three:
Table three: after treatment terminates, two groups of tcm symptoms improve
| Tcm symptom | Of the present invention group (30 example) | Placebo group (30 example) |
| Effective | 3 | 1 |
| Effectively | 22 | 1 |
| Invalid | 5 | 28 |
| Total effective rate | 83.3％ | 6.6％ |
Note: through X
2inspection, result is as follows: X
2=39.998, P < 0.0l.
3.4 Ka Shi scorings are compared
Ka Shi marks evaluation methodology: improve: than raising more than >=10 points before treatment after treatment; Stable: unchanged before and after treatment; Reduce: decline more than 10 points than before treatment after treatment.By analysis: of the present invention group, apparently higher than placebo group (P < 0.05), refers to table four:
Table four: after treatment terminates, two groups of patient Ka Shi scorings are compared
| Group | Number of cases | Improve | Stable | Reduce | X 2Value | P value |
| Of the present invention group | 30 | 8(26.7％) | 21(70％) | 1(3.3％) | ||
| Placebo group | 30 | 2(6.7％) | 21(70％) | 7(23.3％) | 7.899 | 0.020 |
Note: through X
2inspection, result is as follows: X
2=7.899, P=0.020 < 0.O5
3.5 vital function Indexes Comparison
This studies the vital function index of two groups of comparison therapy Patients Before And Afters, therefore through statistical analysis, after treatment terminates, two groups of patient's cancer patient vital function indexs have compared significant difference (P < 0.05), and segmentation tumour eliminating and analgesic external side group (30 example) vital function index improves 13 examples (43.3%); Placebo group (30 example) vital function index improves 6 examples (20.0%), and the former is obviously better than the latter, refers to table five:
Table five: two groups of patient's cancer patient vital function Indexes Comparison after treatment terminates
| Group | Number of cases | Improve | Stable | Reduce | Z value | P value |
| Of the present invention group | 30 | 13(43.3％) | 13(43.3％) | 4(13.3％) | ||
| Placebo group | 30 | 6(20.0％) | 15(50.0％) | 9(30.0％) | -2.132 | 0.033 |
Note: through Wilcoxon rank test, result is as follows: Z=-2.132, P=0.033 < 0.05
Conclusion: as fully visible, the quality of life that Chinese medicine composition of the present invention obviously can alleviate cancer pain, reduce the quantity of third order convergence medicine, improves patient.
4. technological improvement
In preclinical research process, have 3 routine patients to occur the untoward reaction such as skin injury, allergy, erythra, untoward reaction rate is 10%.Inventor is in order to address this problem, carry out again test repeatedly, the basis of original prescription adds Flos Rhododendri Mollis, Caulis Erycibes, Ramulus Cinnamomi three taste medicine, respectively as ministerial drug and make medicine, all medicine property of medicine is concocted again while strengthening the efficacy of a drug, through 30 routine clinical verifications, the course for the treatment of can shorten within 10 days by original 14 days, and none routine skin adverse reaction.
4.1 model case
Case one: bone metastases of lung cancer
Zhao, female, 69 years old, in August, 2010 is diagnosed as right lung adenocarcinoma in Beijing Tumour Hospital, after in this institute's row chemotherapy, surrounding after date, evaluate SD, in January, 2011 check finds thoracic vertebra transfer, Gate of Pervasive Peace hospital row therapy of combining Chinese and Western medicine afterwards, back pain, NRS scoring is 6 points, with two ladder analgesic treatments, effect can not be satisfied with, and use the embodiment of the present invention 2 decoction for the treatment after 10 days after being admitted to hospital, pain obviously alleviates, mark 3 points (still with two ladder analgesic treatments), have no adverse reaction.
Case two: prostate cancer with osseous metastasis
Zhu, man, 64 years old, in December, 2010 was diagnosed as carcinoma of prostate in Cancer Hospital of Chinese Academy of Medical Sciences, seeds implantation, rear because of chest pain, ECT is diagnosed as: multiple rib shifts, rear row radiotherapy, after 4 months, feel again pain, rear hospitalization, pain scores 5 points, take tramadol treatment voluntarily, curative effect is general, after use the external application of the embodiment of the present invention 2 side medicine, after 7 days, pain obviously alleviates, mark 2 points, take indomethacin and get final product pain relieving, have no adverse reaction.
Case three: hepatocarcinoma
Song, female, 76 years old, in January, 2011 was diagnosed as hepatocarcinoma in Friendship Hospital, row interventional therapy 1 time, after be hospitalized for treatment, private prosecution hepatalgia, mark 6 points, inspection is shown: liver distributes lesser tubercle, consider recurrence.Give the embodiment of the present invention 2 side medicine external application for curing in ward, conscious pain alleviates gradually, and after 8 days, pain is very unobvious, and after 14 days, pain scores 2 points, has no adverse reaction, good results.
Case four: left lung cancer accompanied with hydrothorax
Lee, man, 74 years old, in October, 2011 was diagnosed as left pulmonary carcinoma in tumour hospital of medical courses in general institute, left thoracic cavity hydrops, chemotherapy 4 cycle, evaluated SD; Extract hydrothorax partial perfusion chemotherapy, aftersensation in March chest pain is obvious, check CT: swollen thing is comparatively front bigger, a large amount of hydrothorax.Pain scores 7 points, need use Morphine treatment during pain, live into my institute, give the embodiment of the present invention 2 decoction for the treatment, and after 7 days, pain relief, marks 4 points, have no adverse reaction, with morphine comparatively front prolongation interval time, and satisfactory effect.
Case five: the esophageal carcinoma
Cui, man, 55 years old, in August, 2011 is diagnosed as the esophageal carcinoma in BJ Union Hospital, and rear row radiotherapy, after February, retrosternal pain is still comparatively obvious, comes my institute, after being admitted to hospital for asking further therapy of combining Chinese and Western medicine, pain scores 5 points, gives the embodiment of the present invention 2 decoction for the treatment, treats after 7 days, pain comparatively before alleviates, and marks 2 points, treats without the need to analgesic drug product, have no adverse reaction, satisfactory effect.
Detailed description of the invention
Embodiment 1:
Prescription: Sanguis Draxonis 30g, Venenum Bufonis 5g, Rhizoma Arisaematis 75g, Radix Aconiti 75g, Indigo Naturalis 30g, Borneolum Syntheticum 30g, Olibanum 60g, Myrrha 60g.
Usage: ground to the powder by each crude drug, crosses 200 mesh sieves, obtains fine powder.Before using, clean painful area, then by medicamental pulverata boiled water furnishing pasty state, divides in Gypsum Fibrosum cotton pad, thickness is about 0.3cm, and area diameter is about greater than painful area skin 2cm, order mulching one deck gauze on ointment, layer of plastic film, and close fixing with desensitization adhesive plaster.Every day 1 time, application time 8 ~ 12h.
Embodiment 2:
Prescription: Sanguis Draxonis 30g, Venenum Bufonis 5g, Rhizoma Arisaematis 75g, Radix Aconiti 75g, Indigo Naturalis 30g, Borneolum Syntheticum 30g, Olibanum 60g, Myrrha 60g, Flos Rhododendri Mollis 3g, Caulis Erycibes 30g, Ramulus Cinnamomi 50g.
Usage: ground to the powder by each crude drug, crosses 200 mesh sieves, obtains fine powder.Before using, clean painful area, then by medicamental pulverata boiled water furnishing pasty state, divides in Gypsum Fibrosum cotton pad, thickness is about 0.3cm, and area diameter is about greater than painful area skin 2cm, order mulching one deck gauze on ointment, layer of plastic film, and close fixing with desensitization adhesive plaster.Every day 1 time, application time 8 ~ 12h.
Embodiment 3:
The present invention commonly uses crude drug composition and proportioning situation (g)
| Fang Hao | Sanguis Draxonis | Venenum Bufonis | Rhizoma Arisaematis | Radix Aconiti | Indigo Naturalis | Borneolum Syntheticum | Olibanum | Myrrha | Flos Rhododendri Mollis | Caulis Erycibes | Ramulus Cinnamomi |
| 1 | 25 | 4 | 60 | 60 | 25 | 25 | 50 | 50 | 0 | 0 | 0 |
| 2 | 35 | 6 | 90 | 90 | 35 | 35 | 70 | 70 | 0 | 0 | 0 |
| 3 | 30 | 5 | 75 | 75 | 30 | 30 | 60 | 60 | 0 | 0 | 0 |
| 4 | 25 | 4 | 60 | 60 | 25 | 25 | 70 | 70 | 0 | 0 | 0 |
| 5 | 35 | 6 | 90 | 90 | 35 | 35 | 50 | 50 | 0 | 0 | 0 |
| 6 | 30 | 5 | 75 | 60 | 25 | 25 | 70 | 70 | 0 | 0 | 0 |
| 7 | 25 | 4 | 60 | 60 | 25 | 25 | 50 | 50 | 2.5 | 25 | 40 |
| 8 | 35 | 6 | 90 | 90 | 35 | 35 | 70 | 70 | 3.5 | 35 | 60 |
| 9 | 30 | 5 | 75 | 75 | 30 | 30 | 60 | 60 | 3 | 30 | 50 |
| 10 | 25 | 4 | 60 | 60 | 25 | 25 | 70 | 70 | 3.5 | 35 | 60 |
| 11 | 35 | 6 | 90 | 90 | 35 | 35 | 50 | 50 | 2.5 | 25 | 40 |
| 12 | 30 | 5 | 75 | 60 | 25 | 25 | 70 | 70 | 3.5 | 30 | 50 |
Above-mentioned each side, pulverizes each crude drug as fine powder, can need to make the exterior-applied formulations such as externally dressing, rubber-emplastrum, unguentum, cataplasma, all can obtain the effect that the present invention claims according to clinical.
Claims (7)
1. be used for the treatment of an external medicine composition for cancer pain, it is characterized in that the effective ingredient of this Chinese medicine composition is made up of the crude drug of following weight ratio: Sanguis Draxonis 25-35 part, Venenum Bufonis 4-6 part, Rhizoma Arisaematis 60-90 part, Radix Aconiti 60-90 part, Indigo Naturalis 25-35 part, Borneolum Syntheticum 25-35 part, Olibanum 50-70 part, Myrrha 50-70 part.
2. external medicine composition according to claim 1, is characterized in that consisting of of each crude drug: Sanguis Draxonis 30 parts, Venenum Bufonis 5 parts, Rhizoma Arisaematis 75 parts, Radix Aconiti 75 parts, Indigo Naturalis 30 parts, Borneolum Syntheticum 30 parts, Olibanum 60 parts, Myrrha 60 parts.
3. be used for the treatment of an external medicine composition for cancer pain, it is characterized in that the effective ingredient of this Chinese medicine composition is made up of the crude drug of following weight ratio: Sanguis Draxonis 25-35 part, Venenum Bufonis 4-6 part, Rhizoma Arisaematis 60-90 part, Radix Aconiti 60-90 part, Indigo Naturalis 25-35 part, Borneolum Syntheticum 25-35 part, Olibanum 50-70 part, Myrrha 50-70 part, Flos Rhododendri Mollis 2.5-3.5 part, Caulis Erycibes 25-35 part, Ramulus Cinnamomi 40-60 part.
4. external medicine composition according to claim 3, is characterized in that consisting of of each crude drug: Sanguis Draxonis 30 parts, Venenum Bufonis 5 parts, Rhizoma Arisaematis 75 parts, Radix Aconiti 75 parts, Indigo Naturalis 30 parts, Borneolum Syntheticum 30 parts, Olibanum 60 parts, Myrrha 60 parts, Flos Rhododendri Mollis 3 parts, Caulis Erycibes 30 parts, Ramulus Cinnamomi 50 parts.
5. external medicine composition according to claim 1 and 2, is characterized in that said composition is made as follows: by all crude drug pulverizations, crosses 200 mesh sieves, adds suitable adjuvant, make externally used paste or patch.
6. the external medicine composition according to claim 3 or 4, is characterized in that said composition is made as follows: by all crude drug pulverizations, crosses 200 mesh sieves, adds suitable adjuvant, make externally used paste or patch.
7. in Claims 1-4 arbitrary described external medicine composition for the preparation of the application in the medicine for the treatment of of cancer pain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675585.1A CN105168723B (en) | 2015-10-19 | 2015-10-19 | A topical Chinese medicinal composition for treating cancer pain, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675585.1A CN105168723B (en) | 2015-10-19 | 2015-10-19 | A topical Chinese medicinal composition for treating cancer pain, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105168723A true CN105168723A (en) | 2015-12-23 |
| CN105168723B CN105168723B (en) | 2020-01-17 |
Family
ID=54891474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510675585.1A Active CN105168723B (en) | 2015-10-19 | 2015-10-19 | A topical Chinese medicinal composition for treating cancer pain, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168723B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389742A (en) * | 2016-10-09 | 2017-02-15 | 上海民生志远健康管理科技发展有限公司 | Traditional Chinese medicine composition for curing cancer pain |
| CN108567964A (en) * | 2018-07-06 | 2018-09-25 | 昆明市中医医院 | Tumour eliminating and analgesic cream |
| CN113476407A (en) * | 2021-08-06 | 2021-10-08 | 孙栋梁 | Gangrene clearing and applying powder and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110598A (en) * | 1995-01-13 | 1995-10-25 | 李勤 | Hot application for stopping cancer pain |
-
2015
- 2015-10-19 CN CN201510675585.1A patent/CN105168723B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110598A (en) * | 1995-01-13 | 1995-10-25 | 李勤 | Hot application for stopping cancer pain |
Non-Patent Citations (1)
| Title |
|---|
| 刘伟胜等主编: "《中医肿瘤、呼吸病临证证治》", 30 November 1999 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389742A (en) * | 2016-10-09 | 2017-02-15 | 上海民生志远健康管理科技发展有限公司 | Traditional Chinese medicine composition for curing cancer pain |
| CN108567964A (en) * | 2018-07-06 | 2018-09-25 | 昆明市中医医院 | Tumour eliminating and analgesic cream |
| CN113476407A (en) * | 2021-08-06 | 2021-10-08 | 孙栋梁 | Gangrene clearing and applying powder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105168723B (en) | 2020-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101491663B (en) | Traditional Chinese medicine composition for treating various cancer | |
| CN105535694A (en) | Traditional Chinese medicine composition for treating hyperuricemia | |
| CN104306837A (en) | Baibei anti-tuberculosis pill for treating pulmonary tuberculosis, tuberculous pleuritis, peritonitis, empyema and bronchopleural fistula | |
| CN105168723A (en) | External traditional Chinese medicine composition for treating cancer pain and preparation method thereof | |
| CN102258603B (en) | Medicinal preparation for treating plasma cell mastitis and preparation method thereof | |
| CN106176784A (en) | A kind of pharmaceutical composition for dermatitis, application, preparation and preparation method thereof | |
| CN105079188A (en) | Traditional Chinese medicine composition for treating anaphylactoid purpura | |
| CN102552804B (en) | Chinese medicine composite for curing verruca plantaris | |
| CN102824576B (en) | Traditional Chinese medicinal composition for treating psoriasis and preparation method thereof | |
| CN101647943B (en) | Medicinal composition | |
| CN104436121B (en) | It is a kind of to treat irregular menstruation, small distention and fullness in the abdomen, the medicine to fail to be impregnated for a long time | |
| CN103655768B (en) | Chinese medicine composition for the treatment of cold-dampness type knee osteoarthritis and preparation method thereof | |
| CN103655814B (en) | One treats psoriatic Chinese medicine composition and application thereof | |
| CN101647935B (en) | Medicinal composition | |
| CN104258210A (en) | Chinese herbal medicine composition for treating psoriasis and preparation method thereof | |
| CN103285161A (en) | Anti-virus traditional Chinese medicinal composition and preparation method thereof | |
| CN102166340B (en) | Chinese medicine composition for treating sthenia heat edema | |
| CN102600427B (en) | Chinese medicinal composition for treating hyperplasia of mammary glands and breast cancer | |
| CN102423369B (en) | Chinese medicinal composition for preventing or treating ovarian cancer | |
| CN104491765B (en) | A kind of medical composition and its use for the treatment of nodules of the breast | |
| CN101244181A (en) | Plaster for bone paralysis with function of qufengshengshi, blood circulation activating and stasis removing, and removing the obstruction in the channels to relieve pain, and preparation thereof | |
| CN105079772A (en) | Traditional Chinese medicine composition for treating early postoperative adhesive intestinal obstruction | |
| CN101862395A (en) | Tumor curing medicine containing saussurea involucrate and preparation method thereof | |
| CN105232661A (en) | Traditional Chinese medicine composition for treating mastitis and preparation method thereof | |
| CN105079310A (en) | Traditional Chinese medicine composition for relieving pain and method for preparing traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |